CAS 154229-19-3
:Abirateron
- (3Beta)-17-(Pyridin-3-Yl)Androsta-5,16-Dien-3-Ol
- (3b)-17-(3-pyridinyl)-Androsta-5,16-dien-3-ol
- 17-(3-Pyridinyl)-androsta-5,16-dien-3β-ol
- 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
- Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3β)-
- Cb 7598
- Abiraterone
Abiraterone
CAS:Formel:C24H31NOReinheit:>98.0%(HPLC)Farbe und Form:White to Almost white powder to crystalMolekulargewicht:349.52Abiraterone
CAS:Abiraterone (CB-7598) (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM).Formel:C24H31NOReinheit:99.18% - 99.93%Farbe und Form:White SolidMolekulargewicht:349.51(1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-ol
CAS:Formel:C24H31NOReinheit:99%Farbe und Form:SolidMolekulargewicht:349.5090Abiraterone
CAS:Formel:C24H31NOReinheit:≥ 99.0%Farbe und Form:Off-white powderMolekulargewicht:349.51Abiraterone Sulfate Sodium Salt
CAS:Stability Hygroscopic
Applications Abiraterone Sulfate is an analogue of Abiraterone (A108490).Formel:C24H30NO4S·NaFarbe und Form:NeatMolekulargewicht:451.55Abiraterone
CAS:Kontrolliertes ProduktApplications Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
References Denis, L., et al.: Cancer, 72, 3888 (1993); Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995); Denmeade, S., et al.: Nat. Rev., 2, 389 (2002); Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005);Formel:C24H31NOFarbe und Form:WhiteMolekulargewicht:349.51Abiraterone N-Oxide Sulfate Sodium Salt
CAS:Applications Abiraterone N-Oxide Sulfate is an analogue of Abiraterone (A108490).
Formel:C24H30NO5S·NaFarbe und Form:NeatMolekulargewicht:467.5535Abiraterone - Bio-X ™
CAS:Kontrolliertes ProduktAbiraterone is an anti-cancer drug that has been shown to be effective in treating prostate cancer. It works by blocking the production of testosterone by inhibiting androgen synthesis. Abiraterone does this by inhibiting CYP17A1, which converts cholesterol into pregnenolone, and then into progesterone and testosterone. Furthermore, it binds to the enzyme steroid 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). Abiraterone is usually a last resort for patients who have stopped responding to other lines of hormone therapies, which is known as second-line therapy.
Formel:C24H31NOReinheit:Min. 95%Farbe und Form:PowderMolekulargewicht:349.51 g/molAbiraterone
CAS:Kontrolliertes ProduktCYP17 enzyme inhibitor
Formel:C24H31NOReinheit:Min. 95%Farbe und Form:White PowderMolekulargewicht:349.51 g/mol(3-β)-17-(3-Pyridinyl)-androsta-5,16-dien-3-ol
CAS:Formel:C24H31NOReinheit:99%Farbe und Form:SolidMolekulargewicht:349.518









